Geron Corp

2025 Financial Guidance For fiscal year 2025, the Company maintains its previously announced expectations of total operating expenses to be in the range of approximately $270 million to $285 million, which includes non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization.

SEC original ↗Geron Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The amendment also extended the date before which any Term Loan prepayment is subject to a make whole premium, or the Makewhole Date, from November 1, 2026 to May 1, 2027.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

The unamortized debt issuance costs will continue to be amortized over the remaining term using a revised effective interest rate.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

The Pharmakon Loan Agreement requires we pay an amount equal to 2.50 % of the Lenders total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by 3 % if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, 2 % if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and 1 % if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

In addition to the prepayment premium, prepayments of any Term Loan prior to May 1, 2027 are subject to a make-whole amount equal to the sum of all interest that would have accrued through such date.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

We are pleased that our sharpened sales strategy is demonstrating signs of commercial success as evidenced by solid U.

SEC original ↗Geron Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.

SEC original ↗Geron Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These risks and uncertainties, include, without limitation, risks and uncertainties related to (a) whether Geron is successful in commercializing RYTELO for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO s approved indication (b) whether the FDA and European Commission will approve imetelstat for other indications on the timelines expected, or at all (c) Geron s plans to commercialize RYTELO in the EU and risks related to operating outside of the U.

SEC original ↗Geron Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron s filings and periodic reports filed with the Securities and Exchange Commission under the heading Risk Factors and elsewhere in such filings and reports, including Geron s quarterly report on Form 10-Q for the quarter ended March 31, 2025, and subsequent filings and reports by Geron.

SEC original ↗Geron Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

OTHER INFORMATION Item 1: Legal Proceedings 38 Item 1A: Risk Factors 38 Item 2: Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 86 Item 3: Defaults Upon Senior Securities 86 Item 4: Mine Safety Disclosures 87 Item 5: Other Information 87 Item 6: Exhibits 87 SIGNATURES 88 RYTELO and other trademarks or service marks of Geron Corporation appearing in this Quarterly Report on Form 10-Q (this "Report") are the property of Geron Corporation.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

COMMITMENTS AND CONTINGENCIES Legal Proceedings On March 13 and March 14, 2025, we and certain of our current and former officers were named as defendants in two putative securities class action lawsuits filed in the United States District Court for the Northern District of California captioned Dabestani v.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026

Both lawsuits allege violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with allegedly false and misleading statements concerning the commercial potential of RYTELO.

SEC original ↗Geron Corp — 10-Q Quarterly report10-QAug 5, 2026